Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Liliana Baila, Stefan Suciu, Petra Muus, Sergio Amadori, Michel Delforge, Gert Ossenkoppele, Dominik L.D. Selleslag, Antoine Thyss, Hilde Demuynk, Alain Gadisseur, P. Vermeulen, Carla De Boer, Heinz Zwierzina, T.M. de Witte

Blood (2007) 110 (11): 1456.

https://doi.org/10.1182/blood.V110.11.1456.1456

Published: 2007

Journal Articles

Aberrant Expression in Human Epithelial Cancers of the P2X5-Encoded Minor Histocompatibility Antigen LRH-1: Implications for Graft-Versus-Tumor Immunity Against Solid Tumors.

Harry Dolstra, PhD, Henriette Levenga, MD, Ingrid Overes, MSc, Johanna C.M. Vos, BSc, Agnes van Horssen-Zoetbrood, BSc, Robbert van der Voort, PhD, Pieter de Mulder, MD, PhD, T.M. de Witte, MD, PhD

Blood (2007) 110 (11): 1795.

https://doi.org/10.1182/blood.V110.11.1795.1795

Published: 2007

Journal Articles

A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).

Blood (2006) 108 (11): 54.

https://doi.org/10.1182/blood.V108.11.54.54

Published: 2006

Journal Articles

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

T.M. de Witte, MD, Ronald Brand, PhD, Anja van Biezen, Ghulam Mufti, MD, Tapani Ruutu, MD, Jurgen Finke, MD, Peter von dem Borne, MD, Antonin Vitek, MD, Michel Delforge, MD, Paolo E. Alessandrino, MD, Nicholas Harhalakis, MD, Nigel H. Russell, MD, Enric Carreras, MD, Leo F. Verdonck, MD, Dietger W. Niederwieser, MD

Blood (2006) 108 (11): 519.

https://doi.org/10.1182/blood.V108.11.519.519

Published: 2006

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Myelodysplastic Syndromes 50 Years or Older. A Retrospective Survey from the EBMT.

ZiYi Lim, Ronald Brand, Anja van Biezen, Jurgen Finke, Dietger W. Niederwieser, Tapani Ruutu, Rodrigo Martino, Andrea Bacigalupo, Axel Arthur Fauser, Gerhard Ehninger, Noel-Jean Milpied, Donald Bunjes, Nicolaus Kroger, Ghulam Mufti, T.M. de Witte

Blood (2006) 108 (11): 520.

https://doi.org/10.1182/blood.V108.11.520.520

Published: 2006

Journal Articles

Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.

Ingrid Overes, Hanny Fredrix, Bjorn de Rijke, Agnes van Horssen-Zoetbrood, Han van Krieken, Reinier Raymakers, Robbert van der Voort, T.M. de Witte, Harry Dolstra

Blood (2006) 108 (11): 138.

https://doi.org/10.1182/blood.V108.11.138.138

Published: 2006

Journal Articles

Human CD34+ Myeloid Leukemic Progenitor Cells Are Susceptible to Lysis by Minor Histocompatibility Antigen LRH-1-Specific Cytotoxic T Lymphocytes.

Harry Dolstra, PhD, Ingrid Overes, Inge Jedema, PhD, Annemieke Vos, Agnes van Horssen-Zoetbrood, Wieger Norde, Robbert van der Voort, PhD, J.H. Frederik Falkenburg, MD, PhD, Anton V. Schattenberg, MD, PhD, T.M. de Witte, MD, PhD

Blood (2006) 108 (11): 134.

https://doi.org/10.1182/blood.V108.11.134.134

Published: 2006

Journal Articles

Vaccination with Host Dendritic Cells Induces Graft-Versus-Leukemia Responses without Severe Graft-Versus-Host Disease in a Preclinical Mouse Model for Allogeneic Stem Cell Transplantation.

Robbert van der Voort, PhD, Jurjen Ruben, BSc, Annemieke Vos, BSc, Marielle Philippens, MD, T.M. de Witte, MD, PhD, Harry Dolstra, PhD

Blood (2006) 108 (11): 3239.

https://doi.org/10.1182/blood.V108.11.3239.3239

Published: 2006

Journal Articles

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplant: May We Predict Graft vs Leukemia without Graft vs Host Disease?.

Cesare Guglielmi, Stefania Bergantini, Simona Iacobelli, Anja van Biezen, Eduardo Olavarria, Alois Gratwohl, Antonius V.M.B. Schattenberg, Leo F. Verdonck, Dietger W. Niederwieser, T.M. de Witte, for the Chronic Leukemia Working Party of the EBMT

Blood (2006) 108 (11): 263.

https://doi.org/10.1182/blood.V108.11.263.263

Published: 2006

Journal Articles

Impact of Relapse after Allogeneic Hematopoietic Stem Cell Transplant on Subsequent Outcome in Patients with Chronic Myeloid Leukemia: A Better Understanding through Multi-State Modeling.

Cesare Guglielmi, Marta Fiocco, Ronald Brand, Eduardo Olavarria, Simona Iacobelli, Hein Putter, Dietger W. Niederwieser, T.M. de Witte, Alois Gratwohl, for the Chronic Leukemia Working Party of the EBMT

Blood (2006) 108 (11): 3666.

https://doi.org/10.1182/blood.V108.11.3666.3666

Published: 2006

Journal Articles

High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) - GIMEMA AML-12 Trial.

Blood (2006) 108 (11): 609.

https://doi.org/10.1182/blood.V108.11.609.609

Published: 2006

Journal Articles

The Balance in Chimerism between T Cells and Blood Dendritic Cells in Relapsed CML Patients Influences the Induction of Alloreactivity Following Donor Lymphocyte Infusion.

Henriette Levenga, Rob Woestenenk, Antonius V.M.B. Schattenberg, Frans Maas, Joop H. Jansen, Reinier Raymakers, Pieter H.M. De Mulder, Nicolaas Schaap, T.M. de Witte, Harry Dolstra

Blood (2006) 108 (11): 5139.

https://doi.org/10.1182/blood.V108.11.5139.5139

Published: 2006

Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

Blood (2005) 106 (11): 794.

https://doi.org/10.1182/blood.V106.11.794.794

Published: 2005

Journal Articles

Outcome of Patients with Myelodysplastic Syndromes (MDS) Undergoing Allogeneic Myeloablative Transplantation: A Retrospective Analysis Comparing HLA Matched Unrelated Donor Bone Marrow Transplantation (BMT) to HLA Identical Sibling SCT. A Retrospective Study on Behalf of the EBMT - Chronic Leukemia Working Party.

Ph. Guardiola, W. Fibbe, T. Ruutu, L. Verdonck, U.W. Schaefer, E. Gluckman, G. Verhoef, J.J. Cornelissen, E. Carreras, N.H. Russel, D. Selleslag, A. Vitek, F. Locatelli, E. Alessandrino, H. Schouten, A. van Biezen, R. Brand, D. Niederwieser, T.M. de Witte

Blood (2004) 104 (11): 1427.

https://doi.org/10.1182/blood.V104.11.1427.1427

Published: 2004

NARROW

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Aberrant Expression in Human Epithelial Cancers of the P2X5-Encoded Minor Histocompatibility Antigen LRH-1: Implications for Graft-Versus-Tumor Immunity Against Solid Tumors.

A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Myelodysplastic Syndromes 50 Years or Older. A Retrospective Survey from the EBMT.

Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.

Human CD34+ Myeloid Leukemic Progenitor Cells Are Susceptible to Lysis by Minor Histocompatibility Antigen LRH-1-Specific Cytotoxic T Lymphocytes.

Vaccination with Host Dendritic Cells Induces Graft-Versus-Leukemia Responses without Severe Graft-Versus-Host Disease in a Preclinical Mouse Model for Allogeneic Stem Cell Transplantation.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplant: May We Predict Graft vs Leukemia without Graft vs Host Disease?.

Impact of Relapse after Allogeneic Hematopoietic Stem Cell Transplant on Subsequent Outcome in Patients with Chronic Myeloid Leukemia: A Better Understanding through Multi-State Modeling.

High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) - GIMEMA AML-12 Trial.

The Balance in Chimerism between T Cells and Blood Dendritic Cells in Relapsed CML Patients Influences the Induction of Alloreactivity Following Donor Lymphocyte Infusion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only